CLINICAL TRIALS PROFILE FOR POSITIVE SKIN TEST CONTROL - HISTAMINE

All Clinical Trials for POSITIVE SKIN TEST CONTROL - HISTAMINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00206440 ↗	Nexium Study To Suppress Nausea During Chemotherapy	Terminated	AstraZeneca	Phase 3	2005-08-01	This study will look at a drug called esomeprazole, the newest PPI, as a way to further reduce the amount of nausea and vomiting seen in breast cancer patients receiving adriamycin or epirubicin chemotherapy. Esomeprazole may help protect the gut lining from the stomach acid and thus lessen the nausea and vomiting. If patients have less stomach sickness, they may be able to enjoy their daily routines much more while they are getting chemotherapy.
NCT00206440 ↗	Nexium Study To Suppress Nausea During Chemotherapy	Terminated	Baylor Breast Care Center	Phase 3	2005-08-01	This study will look at a drug called esomeprazole, the newest PPI, as a way to further reduce the amount of nausea and vomiting seen in breast cancer patients receiving adriamycin or epirubicin chemotherapy. Esomeprazole may help protect the gut lining from the stomach acid and thus lessen the nausea and vomiting. If patients have less stomach sickness, they may be able to enjoy their daily routines much more while they are getting chemotherapy.
NCT01204866 ↗	Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	2010-07-01	The purpose of this study is to determine if Valortim, or one or more of its selected formulation components, induces a wheal reaction when introduced percutaneously. Two of 4 subjects dosed in a previous study with a modified formulation of Valortim experienced treatment related adverse events which were suggestive of allergic or allergic-like reactions. In order to better characterize these reactions and determine if they represent allergic or allergic-like reactions to Valortim or one or more of its components, skin testing of Valortim and selected components on naïve and Valortim-exposed subjects will be performed in this study

Clinical Trial Conditions for POSITIVE SKIN TEST CONTROL - HISTAMINE

Condition Name

Condition Name for POSITIVE SKIN TEST CONTROL - HISTAMINE
Intervention	Trials
Nausea	1
Coronary Artery Disease	1
Respiratory Tract Diseases	1

Condition MeSH

Condition MeSH for POSITIVE SKIN TEST CONTROL - HISTAMINE
Intervention	Trials
Hypersensitivity	3
Rhinitis, Allergic	2
Rhinitis	2

Clinical Trial Locations for POSITIVE SKIN TEST CONTROL - HISTAMINE

Trials by Country

Trials by Country for POSITIVE SKIN TEST CONTROL - HISTAMINE
Location	Trials
United States	16
Brazil	2
Bangladesh	2
Belgium	1
Switzerland	1

Trials by US State

Trials by US State for POSITIVE SKIN TEST CONTROL - HISTAMINE
Location	Trials
Oregon	1
Nebraska	1
Missouri	1
Minnesota	1
Georgia	1

Clinical Trial Progress for POSITIVE SKIN TEST CONTROL - HISTAMINE

Clinical Trial Phase

Clinical Trial Phase for POSITIVE SKIN TEST CONTROL - HISTAMINE
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	5
Phase 2	2

Clinical Trial Status

Clinical Trial Status for POSITIVE SKIN TEST CONTROL - HISTAMINE
Clinical Trial Phase	Trials
Completed	7
Recruiting	3
Active, not recruiting	2

Clinical Trial Sponsors for POSITIVE SKIN TEST CONTROL - HISTAMINE

Sponsor Name

Sponsor Name for POSITIVE SKIN TEST CONTROL - HISTAMINE
Sponsor	Trials
Anhembi Morumbi University	1
AllerQuest LLC	1
Bangladesh Reference Institute of Chemical Measurements (BRICM)	1

Sponsor Type

Sponsor Type for POSITIVE SKIN TEST CONTROL - HISTAMINE
Sponsor	Trials
Other	14
Industry	6
NIH	2